Faizan Farooque

Faizan Farooque

Expertise: Real estate investment trusts (REITs), SPACs, Cryptocurrencies

Education: BSc (Hons) Degree in Applied Accounting, Oxford Brookes University; Introduction to Data Analysis Using Excel, Rice University; Excel Skills for Business: Intermediate, Macquarie University

About Faizan
Faizan Farooque is a finance journalist who has reported on the latest trends in the stock market for many years. He helps people by providing advice about saving and investing and keeping up with what’s happening in the financial world.

Faizan is writing for InvestorPlace.com, GuruFocus, and TipRanks and has previously worked as a financial journalist and data analyst for S&P Global. He can analyze company filings from sources like SEC, FINRA, and others to help identify potential investment opportunities. Researching specific industries is also something he does to provide industry insight for clients.

Faizan deeply understands the market and how to read the financial tea leaves to anticipate where things are headed. His expertise gives readers an insider’s perspective on what’s happening in the finance world so they can make smart decisions.

Recent Articles

5 Stocks to Buy That Have Severed Ties With Trump

These companies make the list of my top stocks to buy because they have a business model that will weather any political or economic storm.

5 Places You Can Buy Cryptocurrency to Play the Volatile Bitcoin Market

Cryptocurrency is on fire these days despite its volatility. Here are five places that you can go to purchase red-hot digital assets.

5 Great Retirement Stocks to Buy for Your Portfolio

Picking retirement stocks is never easy. These five companies offer stable, reliable income streams as you plan out your sunset years.

Ripple Has Become a Cryptocurrency Only for Investors Who Know No Fear

Ripple is a highly risky digital asset in the volatile world of cryptocurrencies. Unless you have a gambler's disposition, Bitcoin is your best bet.

Vaccine Race Is Catching up to Moderna Stock but Outlook Is Solid

Moderna stock is trading at 16 times forward price-to-earnings, quite an unrealistic multiple, considering the vaccine race is tightening.